Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mohammad Hassan Hodroj, Achraf Jardaly, Sarah Abi Raad, Annalise Zouein & Sandra Rizk. (2018) Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway. Cancer Management and Research 10, pages 1079-1088.
Read now
Read now
Articles from other publishers (14)
Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, Jyoti Yadav, Ayuba Akinpelu, Ahmed Alnaim, Harish Kumar, Razan Waliagha, Allison E. Church Bird, Soroush Rais-Bahrami, R. Curtis Bird, Panagiotis Mistriotis, Amarjit Mishra, Clayton C. Yates, Amit K. Mitra & Robert D. Arnold. (2023) Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Research Communications 3:7, pages 1286-1311.
Crossref
Crossref
Joshua T. Davis, Taraswi Mitra Ghosh, Suman Mazumder, Amit Mitra, Richard Curtis Bird & Robert D. Arnold. (2023) Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial–Mesenchymal Transition. International Journal of Molecular Sciences 24:10, pages 8490.
Crossref
Crossref
Mujibur Khan, Md. Mahmudul Hasan, Anne Barnett, Raziye Piranlioglu, Mohammad Rashid, Ahmet Alptekin & Ali Arbab. (2022) Co-axial electrospraying of injectable multi-cancer drugs nanocapsules with polymer shells for targeting aggressive breast cancers. Cancer Nanotechnology 13:1.
Crossref
Crossref
Taraswi Mitra Ghosh, Teeratas Kansom, Suman Mazumder, Joshua Davis, Ahmed S. Alnaim, Shanese L. Jasper, Chu Zhang, Aedan Bird, Praneet Opanasopit, Amit K. Mitra & Robert D. Arnold. (2022) The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion. Journal of Pharmacology and Experimental Therapeutics 380:3, pages 180-201.
Crossref
Crossref
Taraswi Mitra Ghosh, Jason White, Joshua Davis, Suman Mazumder, Teeratas Kansom, Elena Skarupa, Grafton S. Barnett, Gary A. Piazza, R. Curtis Bird, Amit K. Mitra, Clayton Yates, Brian S. Cummings & Robert D. Arnold. (2021) Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
Tuba Tarhan, Bilsen Tural & Servet Tural. (2019) Synthesis and characterization of new branched magnetic nanocomposite for loading and release of topotecan anti-cancer drug. Journal of Analytical Science and Technology 10:1.
Crossref
Crossref
Nhat D. Quach, Sukhneeraj Pal Kaur, Matthew W. Eggert, Lishann Ingram, Deepraj Ghosh, Sheela Sheth, Tamas Nagy, Michelle R. Dawson, Robert D. Arnold & Brian S. Cummings. (2019) Paradoxical Role of Glypican-1 in Prostate Cancer Cell and Tumor Growth. Scientific Reports 9:1.
Crossref
Crossref
Maharjan, Pangeni, Jha, Choi, Chang, Choi, Park & Byun. (2019) Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy. Pharmaceutics 11:7, pages 332.
Crossref
Crossref
Teresa Di Desidero, Ping Xu, Shan Man, Guido Bocci & Robert S. Kerbel. (2015) Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 6:40, pages 42396-42410.
Crossref
Crossref
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Yvonne G. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Jean M. Hansen, William M. Merritt, Alpa M. Nick, Robert R. Langley, Robert L. Coleman & Anil K. Sood. (2015) Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Molecular Cancer Therapeutics 14:12, pages 2677-2686.
Crossref
Crossref
Amar Jyoti, Kyle D. Fugit, Pallavi Sethi, Ronald C. McGarry, Bradley D. Anderson & Meenakshi Upreti. (2015) An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids. Scientific Reports 5:1.
Crossref
Crossref
Antonio Gnoni, Nicola Silvestris, Antonella Licchetta, Daniele Santini, Mario Scartozzi, Roberto Ria, Salvatore Pisconti, Fausto Petrelli, Angelo Vacca & Vito Lorusso. (2015) Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. Critical Reviews in Oncology/Hematology 95:1, pages 46-61.
Crossref
Crossref
Annabelle Chow, Amy Wong, Giulio Francia, Shan Man, Robert S. Kerbel & Urban Emmenegger. (2013) Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Investigational New Drugs 32:1, pages 47-59.
Crossref
Crossref
J. N. Mock, L. J. Costyn, S. L. Wilding, R. D. Arnold & B. S. Cummings. (2013) Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer. Integrative Biology 5:1, pages 172-182.
Crossref
Crossref